Kaleo will provide its Auvi-Q emergency epinephrine auto-injector to many patients at no cost, although the device's list price — which payers will negotiate discounts and rebates from — will be set at $4,500, reports Reuters.
The Richmond, Va.-based drugmaker will relaunch Auvi-Q, a competitor to Mylan's EpiPen, on Feb. 14. A product recall forced the company to pull the device off the market in 2015.
Once the device is on the market, consumers with commercial or federal insurance will be able to obtain Auvi-Q at no charge, Kaleo said in a statement. Individuals with no insurance and a household income under $100,000 will also be eligible to receive the auto-injector for free. Auvi-Q will be sold at a cash price of $360 for those who do not qualify for the discounts.
"In order to help ensure Auvi-Q is available as an option to eligible patients for $0 out-of-pocket, we set the list price at $4,500," Kaleo CEO Spencer Williamson told Reuters via email. "It's important to note that nobody pays the list price, and that the most important price is the price to the patient."
More articles on supply chain:
Supply chain tip of the week: How to manage excessive drug price hikes
Drug shortage spurs FDA to allow use of topical gel approved in Europe
Novartis to consider more US investments amid Trump tax cuts